Mr. Jason Birmingham reports

NOVERIS HEALTH SCIENCES LAUNCHES INVESTOR WEBSITE AND ENGAGES FAIRFAX PARTNERS INC. FOR INVESTOR RELATIONS AND DIGITAL MARKETING SERVICES

Noveris Health Sciences Inc. has launched its new investor-facing website. The website has been developed to provide shareholders, prospective investors and other stakeholders with timely access to corporate information, investor materials and company updates.

The company also announces that it has engaged Fairfax Partners Inc., headquartered in Vancouver, B.C., to provide investor relations management, communications infrastructure and digital marketing services. The engagement for a total of up to $150,000 plus applicable GST is effective March 13, 2026, and is for an initial term of three months.

Under the terms of the agreement, Fairfax Partners will deliver services across four areas. FRAME (communications infrastructure, including investor website development, CRM set-up and digital integration) is provided complimentary. Post! (investor relations management, including drafting and disseminating investor updates, managing inbound communications and disclosure support) is billed at $3,999 per month. MyIR Pro (management of the company's phone system and e-mail inbox, CRM and communications management, and assignment of a dedicated Fair agent -- the world's first agentic investor relations agent and operating system) is billed at $1,195 per month. Fairfax+ (digital marketing campaign execution across Google, LinkedIn and financial platforms) carries a budget of up to $44,000 per month. Including any potential expenses, the engagement represents an aggregate of $50,000 per month plus applicable GST.

"We are excited to take this step forward in building a stronger presence for Noveris Health Sciences in the investment community," said Jason Birmingham, chief executive officer. "The launch of our new website and the engagement of Fairfax Partners reflects our commitment to transparent communication and pro-active outreach to current and prospective investors as we continue to advance our business objectives."

It is hereby disclosed that Fairfax Partners and its directors do not own, directly or indirectly, any shares in the capital of Noveris. The company will file all required regulatory disclosures in connection with this engagement in accordance with applicable securities laws.

About Noveris Health Sciences Inc.

Noveris is a publicly traded biopharmaceutical and life science company focused on the research, development and commercialization of next-generation medications and therapies to address mental health disorders, including nicotine addiction and posttraumatic stress disorder. The company's core strategy blends advanced drug chemistry with artificial intelligence and a robust infrastructure for drug discovery and development, leveraging pharma research capabilities at the University of Alberta to advance its pipeline of patent-pending second-generation compounds. Noveris serves scientific, medical, clinical and veteran organizations worldwide, and is working toward Health Canada and Food and Drug Administration regulatory approvals for its pipeline assets.

We seek Safe Harbor.